By Kelly Knaub ( April 27, 2015, 5:43 PM EDT) -- Sandoz Inc. urged the Federal Circuit to deny Amgen Inc.'s emergency bid to bar Sandoz's launch of the first-ever biosimilar drug under the Affordable Care Act, saying Friday the district court that denied the same request did not abuse its discretion or err in its factual findings....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.